State Key Laboratory Base of Eco-chemical Engineering, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, People's Republic of China.
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China.
J Pharm Biomed Anal. 2023 Jul 5;231:115410. doi: 10.1016/j.jpba.2023.115410. Epub 2023 Apr 20.
In this work, novel potential anthraquinone-temozolomide (TMZ) antitumor hybrids N-(2-((9,10-dioxo-9,10-dihydroanthracen-1-yl)amino)ethyl)-3-methyl-4-oxo-3,4-dihydroimidazo [5, 1-d][1,2,3,5]tetrazine-8-carboxamide (C-1) and 2-(9,10-dioxo-9,10-dihydroanthracen-1-yl)amino) ethyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate (C-9) were designed and synthesized successfully. The electrochemical behaviors of C-1 (C-9) involved the reversible processes of 9,10-anthraquinone ring, the irreversible reduction and oxidation processes of TMZ ring. Electrochemical biosensors were constructed with ctDNA, poly (dG) and poly (dA) modifying the surface of glassy carbon electrode (GCE) to evaluate the DNA oxidative damage caused by the interaction of C-1 (C-9) with DNA. Anthracycline skeleton and TMZ ring in C-1 (C-9) could exhibit bifunctional effects with both intercalating and alkylation modes toward DNA strands. The DNA biosensor had good practicability in mouse serum. The results of gel electrophoresis further demonstrated that C-1 (C-9) could effectively intercalated into ctDNA and disrupt plasmid conformation. Finally, anthraquinone-TMZ hybrid C-1 possessed high cytotoxicity toward A549 and GL261 cells, which could be a novel and optimal candidate for the clinic antitumor treatment.
在这项工作中,设计并成功合成了新型潜在蒽醌-替莫唑胺(TMZ)抗肿瘤杂合 C-1(C-9)。C-1(C-9)的电化学行为涉及 9,10-蒽醌环的可逆过程,TMZ 环的不可逆还原和氧化过程。采用 ctDNA、聚(dG)和聚(dA)修饰玻碳电极(GCE)表面构建电化学生物传感器,以评估 C-1(C-9)与 DNA 相互作用引起的 DNA 氧化损伤。C-1(C-9)中的蒽醌骨架和 TMZ 环可以对 DNA 链表现出双重作用,既有嵌入作用又有烷基化作用。该 DNA 生物传感器在小鼠血清中具有良好的实用性。凝胶电泳的结果进一步证明 C-1(C-9)可以有效地嵌入 ctDNA 并破坏质粒构象。最后,蒽醌-TMZ 杂合 C-1 对 A549 和 GL261 细胞具有高细胞毒性,可能是临床抗肿瘤治疗的新型最佳候选药物。